Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer
The non-dilutive award adds to NIH and Texas research funding already secured for the pancreatic cancer program.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Marker Therapeutics (Nasdaq: MRKR) has been awarded a $2.6 million FDA grant to support development of MT-601 in pancreatic cancer. The non-dilutive funding will support a Phase 1 study in patients with locally advanced unresectable pancreatic cancer, meaning disease that cannot be surgically removed. Marker expects clinical initiation in the first quarter of 2027.
The program builds on a Baylor College of Medicine Phase 1/2 study of multi-antigen targeted T cells combined with frontline chemotherapy. That study reported an 84.6% disease control rate, median response duration of 7.5 months and median overall survival of 14.1 months. Marker described its safety profile as favorable. The planned company-sponsored study will incorporate broader antigen targeting, higher T cell doses and lymphodepletion, a treatment that reduces lymphocytes, with the aim of improving cell persistence and clinical outcomes.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point$2.6 million FDA grant provides non-dilutive funding for the Phase 1 pancreatic cancer study. 15% of market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.Clinical initiation of the MT-601 pancreatic cancer study is expected in the first quarter of 2027.
- Moderate point84.6% disease control rate reported in Baylor’s Phase 1/2 study combining multi-antigen targeted T cells with frontline chemotherapy.
- Minor pointMedian response duration of 7.5 months reported in the Baylor combination-treatment study.
- Minor pointMedian overall survival of 14.1 months reported in the Baylor combination-treatment study.
3 minor points
- Minor pointFavorable safety profile described by Marker for the Baylor combination-treatment study.
- Minor pointNIH SBIR and CPRIT funding already secured provides additional non-dilutive support for the pancreatic cancer program.
- Minor point. Forward-looking: it has not happened yet and may not happen.Expanded antigen targeting, higher T cell doses and lymphodepletion are planned to potentially improve clinical outcomes.
Negative
- None.
Details
Market move: MRKR +6.71% vs previous close. FDA grant award
On Oct 19, the day this news came out, the latest delayed price for MRKR is 6.71% above the previous close. Argus tracked a peak move of +6.5% during the session. Our momentum scanner has recorded 9 alerts for this stock so far that day. The latest delayed price is $1.11.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- FDA grant
- $2.6 million
- Funding to support MT-601 development in pancreatic cancer
- Grant selection
- 6 of 66 applications
- FDA Orphan Products Clinical Trials grants program, fiscal year 2026
- Disease control rate
- 84.6%
- Patients receiving multi-antigen targeted T cells with frontline chemotherapy
- Median duration of response
- 7.5 months
- Phase 1/2 study in pancreatic cancer
- Median overall survival
- 14.1 months
- Phase 1/2 study in pancreatic cancer
- Expected study initiation
- First quarter of 2027
- Company-sponsored MT-601 pancreatic cancer study
Historical Context
-
Expanded CDMO capacity was expected to support MT-601 through clinical development.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
non-dilutive funding financial
antigen escape medical
disease control rate medical
lymphodepletion medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Competitive selection reinforces independent recognition of the scientific rationale and development potential of Marker’s multi-antigen recognizing T cell platform
HOUSTON, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), is a clinical-stage immuno-oncology company developing multi-antigen recognizing (MAR)-T cell therapies under an exclusive worldwide license from Baylor College of Medicine for patients with cancer. Today, Marker announced that the Company has been awarded
The FDA’s Orphan Products Clinical Trials grants program is a highly competitive federal funding initiative designed to support clinical research that may advance the development of treatments for rare diseases. Applications undergo independent scientific peer review, including evaluation of scientific rationale, clinical trial design, feasibility, and potential contribution to product development. In fiscal year 2026, the FDA received 66 applications and selected six projects for funding.
“We are honored to be among the six recipients selected for funding through the FDA’s highly competitive Orphan Products Clinical Trials grants program,” said Juan Vera, MD, President and Chief Executive Officer of Marker Therapeutics. “This award represents meaningful independent recognition and external validation of the scientific rationale underlying our MAR-T platform and its potential application in pancreatic cancer. Our technology is designed to recognize multiple tumor-associated antigens, offering a differentiated approach to addressing tumor heterogeneity and antigen escape, while maintaining the favorable safety profile observed in more than 200 patients treated across our clinical programs in hematologic malignancies and solid tumors. The additional non-dilutive funding from the FDA will further support our efforts to advance MT-601 in an area of significant unmet medical need.”
The FDA grant award further expands Marker’s track record of securing competitive federal and state research funding to support the development of the Company’s innovative MAR-T cell therapies. In addition to the FDA Orphan Products Clinical Trials grant, Marker has secured non-dilutive funding from the National Institutes of Health (NIH) Small Business Innovation Research (SBIR) program and the Cancer Prevention and Research Institute of Texas (CPRIT) to support the pancreatic cancer program.
The clinical development of MT-601 in pancreatic cancer builds on encouraging results from a Phase 1/2 study conducted at Baylor College of Medicine and published in Nature Medicine earlier this year (Musher BL, Vasileiou S, Smaglo BG et al. Nat Med. 2026). The findings also received national coverage on Good Morning America (January 22, 2026). The study demonstrated a favorable safety profile and disease control rate of
“These encouraging clinical findings provide a strong foundation for the development of MT-601 in pancreatic cancer, particularly given the limited outcomes with current treatment options,” commented Dr. Vera. “For context, a recent clinical trial evaluating standard frontline chemotherapy regimens in metastatic pancreatic cancer reported median overall survival of 9.2-11.1 months and median duration of response of 5-7.3 months. Through our company-sponsored study, we aim to build on our previous observations from the Baylor study by incorporating an expanded antigen-targeting profile, higher T cell doses, and lymphodepletion to potentially enhance T cell expansion, persistence, and clinical outcomes. The FDA grant provides important non-dilutive funding and further recognition of the scientific rationale and development potential of our program. We anticipate clinical initiation of our study in pancreatic cancer in the first quarter of 2027 and look forward to advancing MT-601 as a potential treatment option for patients with a significant unmet medical need.”
About the FDA Orphan Products Clinical Trials Grants Program
The U.S. Food and Drug Administration's (FDA) Orphan Products Clinical Trials grants program supports clinical research evaluating the safety and efficacy of investigational products for rare diseases and conditions. The program provides competitive, non-dilutive funding to advance promising therapies through clinical development. Applications undergo a rigorous scientific peer-review process assessing scientific merit, clinical study design, feasibility, and potential impact on patients with unmet medical needs. Since its inception in 1983, the program has supported clinical research contributing to the approval of more than 85 medical products for rare diseases.
About MAR-T cells
The multi-antigen recognizing (MAR) T cell platform (formerly known as multiTAA-specific T cells) is a novel, non-genetically modified cell therapy approach that selectively expands tumor-specific T cells from a patient's/donor’s blood capable of recognizing a broad range of tumor antigens. Unlike other T cell therapies, MAR-T cells allow the recognition of hundreds of different epitopes within up to six tumor-specific antigens, thereby reducing the possibility of tumor escape. Since MAR-T cells are not genetically engineered, Marker believes that its product candidates will be easier and less expensive to manufacture, with an improved safety profile compared to current engineered T cell approaches and may provide patients with meaningful clinical benefits.
About MT-601
The Company’s lead product, MT-601, is a multi-antigen recognizing (MAR) T cell product that utilizes a non-genetically modified approach that specifically targets six different tumor antigens upregulated in tumor cells (Survivin, PRAME, WT-1, NY-ESO-1, SSX-2, MAGEA-4). Marker is currently investigating MT-601 in the Phase 1 APOLLO trial (clinicaltrials.gov identifier: NCT05798897) for the treatment of patients with lymphoma who have relapsed after or are ineligible to receive anti-CD19 CAR-T cell therapies. Due to the broad target recognition profile of MT-601, the Company is exploring its potential application beyond lymphoma in patients with pancreatic cancer. The Company’s pancreatic cancer program is supported by the National Cancer Institute of the National Institutes of Health (Award Number R44CA295168), the Cancer Prevention and Research Institute of Texas (CPRIT, Award Number DP250150), and the Food and Drug Administration Orphan Products Clinical Trials Grants program (Award Number 1R01FD008756-01).
About Marker Therapeutics, Inc.
Marker Therapeutics, Inc. is a Houston, TX-based clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors. The Company was founded at Baylor College of Medicine, and clinical trials that enrolled more than 200 patients across various hematological and solid tumor indications showed that the Company’s autologous and allogeneic MAR-T cell products were well tolerated and demonstrated durable clinical responses. Marker’s goal is to introduce novel T cell therapies to the market and improve patient outcomes. To achieve these objectives, the Company prioritizes the preservation of financial resources and focuses on operational excellence. Marker’s unique T cell platform is strengthened by non-dilutive funding from U.S. state and federal agencies supporting cancer research, including the National Cancer Institute of National Institutes of Health, U.S. Department of War, the FDA Orphan Drug program and the Cancer Prevention Research Institute of Texas (CPRIT).
To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.
Forward-Looking Statements
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; and the timing, conduct, interim results announcements and outcomes of our clinical trials of our product candidates, including neldaleucel (MT-601) for the treatment of patients with pancreatic cancer or lymphoma. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at WWW.SEC.GOV. The Company assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release except as may be required by law.
Media and Investor Contact
Marker Therapeutics, Inc.
+1 (713) 400-6400
investor.relations@markertherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What will Marker Therapeutics’ $2.6 million FDA grant fund?
The $2.6 million award will support a Phase 1 study evaluating MT-601 in patients with locally advanced unresectable pancreatic cancer. It comes through the FDA’s Orphan Products Clinical Trials grants program and provides non-dilutive funding.
When does Marker Therapeutics expect to start its MT-601 pancreatic cancer study?
Marker expects clinical initiation of its company-sponsored pancreatic cancer study in the first quarter of 2027. The planned study builds on earlier Baylor College of Medicine research involving multi-antigen targeted T cells combined with frontline chemotherapy.
How was Marker Therapeutics selected for the FDA orphan products grant?
Marker’s application underwent independent scientific peer review assessing scientific rationale, trial design, feasibility and potential contribution to product development. In fiscal year 2026, the FDA received 66 applications and selected six projects for funding.